. 2021 Nov 1;12:635089. doi: 10.3389/fphar.2021.635089

TABLE 1.

Characteristics of included RCTs.

Author, year	Country	Study design	Participants number	Follow-up duration	Intervention drugs	Treatment outcomes	Adverse events
Overton et al. (2016)	The United States	Phase 4 randomized trial	22	48 weeks	DRV/r	9.9	2/12
					ATV/r	9.1	1/10
					ATV/r	Glucose disposal rate
Noor et al. (2004)	The United States	Randomized, double-blind, crossover study	30	5 days	Placebo	9.88	None
					ATV	9.80
					LPV/r	7.52
					LPV/r	Glucose disposal rate
Noor et al. (2006)	The United States	Randomized, crossover study	26	10 days	ATV/r	10.4	None
					LPV/r	8.6
					LPV/r	Glucose disposal rate
Lee et al. (2007)	The United States	Randomized, double-blind, crossover study	14	28 days	RTV	8.0	1/8
Lee et al. (2007)	The United States	Randomized, double-blind, crossover study	14	28 days	Amprenavir	8.4 glucose disposal rate	0/6
Molina et al. (2010)	Multicenter	Multicenter, open-label, non-inferiority randomized trial	883	96 weeks	ATV/RTV	3/434	283
					LPV/RTV	2/428	282
					LPV/RTV	Hyperglycemia
Stanley et al. (2009)	The United States	Randomized non-blinded trial	12	6 months	ATV/RTV	26.7	3/5
					LPV/RTV	24.4	1/7
					LPV/RTV	Glucose disposal rate
Dubé et al. (2008)	The United States	Placebo-controlled trial	30	4 weeks	ATV/RTV	6.73
					LPV/RTV	8.88
					Placebo	7.53
					Placebo	Mean glucose uptake
Noor et al. (2002)	The United States	Randomized placebo-controlled trial	06	7–10 days	IDV	13.5
					Placebo	14.1
					Placebo	Glucose disposal rate
Randell et al. (2010)	The United Kingdom	Randomized trial	27	2 weeks	FPV	4.48
					LPV	0.28
					LPV	M/I (ratio of glucose disposal rate)

DRV, darunavir; ATV, atazanavir; IDV, indinavir; RTV, ritsonavir; LPV, lopinavir; FPV, fosamprenavir.